Diabetes (Type 2 Diabetes)

Clinical Trial Finder

Many patients with type 2 diabetes are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Risk Assessment of Type 2 Diabetes in Pharmacies

Condition:   Type2 Diabetes
Intervention:   Other: Diabetes risk assessment service in Norwegian community pharmacies
Sponsor:   University of Bergen
Completed

Longitudinal Assessment of Multiple Organs in Patients With Type 2 Diabetes

Condition:   Type 2 Diabetes
Intervention:   Other: Multi parametric MRI scan
Sponsors:   Perspectum Diagnostics Ltd;   University of Liverpool;   Aintree University Hospitals NHS Foundation Trust;   Oxford University Hospitals NHS Trust;   Royal Free Hospital NHS Foundation Trust
Not yet recruiting

Glycemic Variability Comparing Two vs Six Meals in Type 2 Diabetes

Conditions:   Diabetes Mellitus Type 2;   Overweight and Obesity;   Meal Time
Intervention:   Other: Comparing 3 versus 6 meals in type 2 diabetes patients
Sponsors:   Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran;   L.N. Adrián Romero Villaseñor;   L.N. Aurora Ramos Flores;   L.N. Mariana Galindo Guzmán;   Dr. Daniel Cuevas Ramos;   Dr. Adrian Soto Mota;   Dr. Francisco J. Gómez Pérez;   Dr. Alfonso Gulias Herrero;   Lucía Palacios Baez;   Gerardo Saavedra Jiménez;   Hector Donaldo Espinosa Salazar;   Issa Lill Santiago Falfán;   Cristina Aurora Tlapanco Beltrán;   Horacio Correa Carranza;   Alejandra Dominguez Sanchez
Recruiting

A Study in Type 2 Diabetic Patients With Repeated Doses of E1 in Combination With G1

Condition:   Type 2 Diabetes
Intervention:   Drug: E1 and G1
Sponsor:   OPKO Health, Inc.
Completed

Genetics of Type 2 Diabetes Among Han Chinese

Conditions:   Diabetes;   Hypertension
Intervention:  
Sponsor:   National Human Genome Research Institute (NHGRI)
Completed

DBPR108 Tablets in Type 2 Diabetes Mellitus Patients

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: DBPR108 tablet(50mg), Placebo matching DBPR108 tablet(100mg);   Drug: DBPR108 tablet(100mg), Placebo matching DBPR108 tablet(50mg), Placebo matching DBPR108 tablet(100mg);   Drug: DBPR108 tablet(100mg), Placebo matching DBPR108 tablet(50mg);   Drug: Placebo matching DBPR108 tablet(100mg), Placebo matching DBPR108 tablet(50mg)
Sponsor:   CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Completed

Study of the Genome, Gut Metagenome and Lifestyle of Patients With Incident Type 2 Diabetes Mellitus

Conditions:   Diabetes Mellitus, Type 2;   Metagenome;   Genetic Predisposition
Interventions:   Diagnostic Test: 16S rRNA gene sequencing;   Genetic: DNA-microarray genotyping
Sponsor:   Atlas Biomed
Not yet recruiting

Therapeutic Effect of Dapagliflozin Combined With CSII on Newly Diagnosed Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Dapagliflozin 10 MG;   Drug: Insulin Aspart
Sponsor:   Nanjing First Hospital, Nanjing Medical University
Not yet recruiting

Efficacy of Ipragliflozin Compared With Sitagliptin in Uncontrolled Type 2 Diabetes With Sulfonylurea and Metformin

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Ipragliflozin;   Drug: Sitagliptin
Sponsors:   Seoul National University Bundang Hospital;   Astellas Pharma Korea, Inc.
Recruiting

Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes Subjects

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Bexagliflozin;   Drug: Sitagliptin;   Drug: Placebo for sitagliptin;   Drug: Placebo for bexagliflozin
Sponsor:   Theracos
Completed

Mitochondrial Methylation in Type 2 Diabetes

Conditions:   Obesity;   Diabetes Mellitus, Type 2;   Insulin Resistance
Intervention:   Other: Methylation status
Sponsor:   University of Arizona
Recruiting

Safety and Efficacy Study of Exenatide Once Weekly in Adolescents With Type 2 Diabetes

Condition:   Children and Adolescent With Type 2 Diabetes
Interventions:   Drug: Exenatide Once Weekly;   Drug: Placebo
Sponsor:   AstraZeneca
Active, not recruiting

Glycaemic Markers in Persons With Type 2 Diabetes on Peritoneal Dialysis

Conditions:   HbA1c;   Peritoneal Diseases;   Glycated Albumin;   Fructosamine;   Continuous Glucose Monitoring
Interventions:   Device: Continuous glucose monitoring;   Diagnostic Test: Glycaemic markers
Sponsors:   Rigshospitalet, Denmark;   Steno Diabetes Center Copenhagen;   Zealand University Hospital;   Herlev Hospital;   Hillerod Hospital, Denmark
Not yet recruiting

Uric Acid Lowering Trial in Youth Onset T2D

Conditions:   Diabetic Kidney Disease;   Hyperuricemia;   Diabetes;   Diabetes Mellitus, Type 2;   Type2 Diabetes;   Type 2 Diabetes Mellitus;   Diabetic Nephropathies;   Diabetes Complications
Intervention:   Drug: Pegloticase 8 MG/ML [Krystexxa]
Sponsor:   University of Colorado Denver School of Medicine Barbara Davis Center
Not yet recruiting

Stem Cells From Human Exfoliated Teeth in Treatment of Type 2 Diabetes

Condition:   Type2 Diabetes
Intervention:   Biological: Stem Cells From Human Exfoliated Teeth
Sponsor:   CAR-T (Shanghai) Biotechnology Co., Ltd.
Recruiting

A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes on Metformin With or Without Sulfonylurea (SURPASS-AP-Combo)

Condition:   Type 2 Diabetes
Interventions:   Drug: Tirzepatide;   Drug: Insulin Glargine
Sponsor:   Eli Lilly and Company
Not yet recruiting

Effects of SGLT2 Inhibition Treatment on Different Levels of Albuminuria in Patients With Type 2 Diabetes

Conditions:   Type 2 Diabetes;   Diabetic Nephropathy
Intervention:   Drug: SGLT2 Inhibition
Sponsor:   Zhongshan Hospital Xiamen University
Recruiting

A Study of LY3209590 in Participants With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: LY3209590;   Drug: Insulin Degludec
Sponsor:   Eli Lilly and Company
Active, not recruiting

A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Drug: Tirzepatide;   Drug: Semaglutide
Sponsor:   Eli Lilly and Company
Recruiting

A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes
Interventions:   Drug: LY2963016;   Drug: Lantus®
Sponsor:   Eli Lilly and Company
Active, not recruiting

A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin

Condition:   Type 2 Diabetes
Interventions:   Drug: Tirzepatide;   Drug: Placebo
Sponsor:   Eli Lilly and Company
Recruiting

A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Tirzepatide;   Drug: Insulin Degludec
Sponsor:   Eli Lilly and Company
Recruiting

A Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Drug: Dulaglutide;   Drug: Placebo
Sponsor:   Eli Lilly and Company
Recruiting

Safety and Efficacy of Bexagliflozin Compared to Placebo as Add-on Therapy to Metformin in Type 2 Diabetes Subjects

Condition:   Type2 Diabetes Mellitus
Interventions:   Drug: Bexagliflozin tablets, 20 mg;   Drug: Bexagliflozin tablets, placebo
Sponsor:   Theracos
Completed

A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Tirzepatide;   Drug: Placebo
Sponsor:   Eli Lilly and Company
Recruiting

A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Tirzepatide;   Drug: Insulin Glargine
Sponsor:   Eli Lilly and Company
Recruiting

Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Bexagliflozin;   Drug: Placebo
Sponsor:   Theracos
Completed

Safety and Efficacy of Bexagliflozin as Monotherapy in Patients With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Bexagliflozin;   Drug: Placebo
Sponsor:   Theracos
Completed

Partners for Better Health in Adolescent Type 2 Diabetes: The Buddy Study

Conditions:   Obesity;   Diabetes Mellitus, Type 2;   Abnormal Glucose Metabolism;   Type 2 Diabetes
Intervention:   Behavioral: Assignment of a Lay Patient Partner
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Completed

The Effect of Sodium Zirconium Cyclosilicate on Albuminuria in Patients With Type 2 Diabetes and Hyperkalemia

Condition:   Type 2 Diabetes Mellitus With Kidney Complications
Interventions:   Drug: LOKELMA 5 GM Powder for Oral Suspension;   Drug: Placebos
Sponsors:   Steno Diabetes Center Copenhagen;   AstraZeneca;   Zealand University Hospital
Recruiting

Efficacy and Safety of Sotagliflozin Versus Placebo in Chinese Patients With Type 2 Diabetes Mellitus Not Adequately Controlled by Diet and Exercise

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: sotagliflozin (SAR439954);   Drug: placebo
Sponsor:   Sanofi
Recruiting

A Study of People With Type 2 Diabetes Who Have Diseases That Affect the Heart and Blood Vessels. The Study Will Also Look at the Treatment of a Group of These People in Hospitals in Portugal

Condition:   Diabetes Mellitus, Type 2
Intervention:   Other: No treatment given
Sponsor:   Novo Nordisk A/S
Enrolling by invitation

Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: efpeglenatide (SAR439977);   Drug: placebo
Sponsor:   Sanofi
Active, not recruiting

Comparison of the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine in Patients With Type 2 Diabetes Insufficiently Controlled on Basal Insulin

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Insulin glargine/Lixisenatide (HOE901/AVE0010);   Drug: Insulin glargine (HOE901);   Drug: Metformin
Sponsor:   Sanofi
Recruiting

Efficacy and Safety of Sotagliflozin Versus Placebo in Chinese Patients With Type 2 Diabetes Mellitus Not Adequately Controlled by Metformin With or Without Sulfonylurea

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: sotagliflozin (SAR439954);   Drug: placebo;   Drug: metformin;   Drug: sulfonylurea
Sponsor:   Sanofi
Recruiting

A Study of the Safety and Effectiveness of LY3053102 in Participants With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: LY3053102;   Drug: Exenatide ER;   Drug: Placebo;   Drug: Metformin
Sponsor:   Eli Lilly and Company
Terminated

Effect of Sotagliflozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial)

Condition:   Heart Failure-Type 2 Diabetes Mellitus
Interventions:   Drug: Sotagliflozin (SAR439954);   Drug: Placebo
Sponsor:   Sanofi
Recruiting

Outcomes of Expanded Autologous Bone Marrow-derived Mesenchymal Stem Cells Therapy in Type II Diabetes

Condition:   Type 2 Diabetes Mellitus
Intervention:   Combination Product: Expanded autologous bone marrow-derived mesenchymal stem cell
Sponsor:   Vinmec Research Institute of Stem Cell and Gene Technology
Completed

A Study to Evaluate Safety and Effects of Sotagliflozin Dose 1 and Dose 2 on Glucose Control in Patients With Type 2 Diabetes, Severe Impairment of Kidney Function and Inadequate Blood Sugar Control

Condition:   Type 2 Diabetes Mellitus-Chronic Kidney Disease Stage 4
Interventions:   Drug: Placebo;   Drug: Sotagliflozin (SAR439954)
Sponsor:   Sanofi
Active, not recruiting

Impact of Body Composition and Exercise on Clinical, Metabolic and Molecular Parameters in Type 2 Diabetics in Qatar

Condition:   Type 2 Diabetes
Intervention:   Behavioral: 10-week exercise programme based on aerobic interval and resistance training
Sponsors:   Hamad Medical Corporation;   Hamad Bin Khalifa University
Recruiting

Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk

Conditions:   Type 2 Diabetes Mellitus;   Chronic Kidney Diseases
Interventions:   Drug: Sotagliflozin (SAR439954);   Drug: Placebo
Sponsor:   Sanofi
Recruiting

Role of Canagliflozin on CD34+ Cells in Patients With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Canagliflozin;   Drug: Placebo
Sponsors:   George Washington University;   Janssen Scientific Affairs, LLC
Recruiting

A Double-blind Study to Assess 2 Doses of an Investigational Product for 16 Weeks in Participants With Non-alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus

Condition:   Non-alcoholic Steatohepatitis
Interventions:   Drug: Placebo;   Drug: PF-06835919
Sponsor:   Pfizer
Recruiting

Effect of Ertugliflozin on Cardiac Function in Diabetes

Conditions:   Type2 Diabetes;   Heart Failure
Interventions:   Drug: Ertugliflozin;   Drug: Placebo
Sponsors:   Soo Lim;   MSD Korea Ltd.
Recruiting

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease

Condition:   Diabetic Kidney Disease
Interventions:   Drug: Finerenone (BAY94-8862);   Drug: Placebo
Sponsor:   Bayer
Active, not recruiting

Ertugliflozin Type 2 Diabetes Mellitus (T2DM) Pediatric Study (MK-8835/PF-04971729) (MK-8835-059)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Ertugliflozin 5 mg;   Drug: Ertugliflozin 15 mg;   Drug: Placebo;   Biological: Insulin;   Drug: Metformin
Sponsors:   Merck Sharp & Dohme Corp.;   Pfizer
Recruiting

Evaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Insulin glargine/Lixisenatide (HOE901/AVE0010);   Drug: Insulin glargine (HOE901);   Drug: Lixisenatide (AVE0010);   Drug: Metformin
Sponsor:   Sanofi
Recruiting

A Study on Safety, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Pediatric Patients With Type 2 Diabetes Mellitus (T2DM)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Lixisenatide (AVE0010);   Drug: Placebo;   Drug: Basal Insulin;   Drug: Metformin
Sponsor:   Sanofi
Recruiting

ORION: Effects of Cenicriviroc on Insulin Sensitivity in Subjects With Prediabetes or Type 2 Diabetes Mellitus (T2DM) and Suspected NAFLD

Conditions:   Prediabetic State;   Non-alcoholic Fatty Liver Disease;   Type 2 Diabetes Mellitus
Interventions:   Drug: Cenicriviroc 150 mg;   Drug: Placebo
Sponsor:   Tobira Therapeutics, Inc.
Completed

Evaluation of Superiority of Valsartan+Celecoxib+Metformin Over Metformin Alone in Type 2 Diabetes Patients

Conditions:   Type 2 Diabetes;   High Blood Pressure;   Arthritis;   Obesity
Interventions:   Drug: Metformin;   Drug: Val, Cel and Met XR Low;   Drug: Val, Cel and Met XR High
Sponsors:   ARKAY Therapeutics;   Albany Medical College
Not yet recruiting

The Study Will Evaluate Average 24-hr Sodium Excretion During Dapagliflozin Treatment in Patients With Type 2 Diabetes Mellitus With Preserved or Impaired Renal Function or Non-diabetics With Impaired Renal Function.

Conditions:   Diabetes Mellitus, Type 2;   Kidney Function Tests
Intervention:   Drug: Dapagliflozin
Sponsor:   AstraZeneca
Recruiting

Effect of Short-Term Beta-Cell Rest in Adolescents and Young Adults With Type 2 Diabetes Mellitus

Conditions:   Obesity;   Overweight;   Diabetes Mellitus, Type 2
Intervention:  
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Completed

Effectiveness of Motivational Interviewing on Improving Care for Type 2 Diabetes Mellitus Patients in China

Condition:   Diabete Type 2
Interventions:   Behavioral: Motivational interviewing (MI)-based patient empowerment program (PEP);   Behavioral: Traditional lecture style health education
Sponsor:   The University of Hong Kong-Shenzhen Hospital
Completed

Study of ISIS 703802 in Subjects With Hypertriglyceridemia, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease

Conditions:   NAFLD;   Diabetes Mellitus, Type 2;   Hypertriglyceridemia;   Fatty Liver, Nonalcoholic
Interventions:   Drug: ISIS 703802;   Drug: Placebo
Sponsors:   Akcea Therapeutics;   Ionis Pharmaceuticals, Inc.
Active, not recruiting

Tenelia Elderly CGMS Study(TEDDY)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Teneligliptin;   Drug: Placebo
Sponsor:   Handok Inc.
Active, not recruiting

Effects of Metformin on Hepatic FFA Metabolism

Conditions:   Type 2 Diabetes;   Dyslipidemia
Interventions:   Drug: Metformin;   Drug: Placebo
Sponsor:   Lars Christian Gormsen
Completed

Treatment Adherence Intervention in Patients With Type 2 Diabetes and Comorbid Depression

Conditions:   Diabetes Mellitus, Type 2;   Depression
Intervention:   Behavioral: Telephone Intervention Group
Sponsors:   Instituto de Investigación Sanitaria Aragón;   Universidad de Zaragoza
Active, not recruiting

Medical Optimization of Management of Type 2 Diabetes Complicating Pregnancy (MOMPOD)

Conditions:   Diabetes;   Pregnancy
Interventions:   Drug: Metformin;   Drug: Placebo
Sponsors:   University of North Carolina, Chapel Hill;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting

Effect of Efpeglenatide on Cardiovascular Outcomes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Efpeglenatide (SAR439977);   Drug: Placebo
Sponsor:   Sanofi
Active, not recruiting

A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Semaglutide;   Drug: Placebo (semaglutide)
Sponsor:   Novo Nordisk A/S
Recruiting

A Study to Observe the Effectiveness of Empagliflozin, Other SGLT-2 Inhibitors, or DPP-4 Inhibitors in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Subjects treated with Empagliflozin or any Sodium-glucose cotransporter-2 (SGLT-2) inhibitor;   Drug: Subjects treated with Dipeptidyl peptidase-4 (DPP-4) inhibitor
Sponsor:   Boehringer Ingelheim
Active, not recruiting

A Study of LY3305677 in Participants With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: LY3305677;   Drug: Placebo
Sponsor:   Eli Lilly and Company
Not yet recruiting

A Research Study, Looking at How Tresiba® Works in People With Type 2 Diabetes in Local Clinical Practice in Saudi Arabia

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Insulin degludec
Sponsor:   Novo Nordisk A/S
Enrolling by invitation

BDPP Treatment for Mild Cognitive Impairment (MCI) and Prediabetes or Type 2 Diabetes Mellitus (T2DM)

Conditions:   Mild Cognitive Impairment;   Alzheimer's Disease
Intervention:   Drug: grape seed polyphenolic extract, resveratrol
Sponsors:   Johns Hopkins University;   Icahn School of Medicine at Mount Sinai
Recruiting

A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Semaglutide;   Drug: Placebo
Sponsor:   Novo Nordisk A/S
Recruiting

A Study to Evaluate Time in Range in Type 2 Diabetics Using Afrezza® Plus Basal Insulin Compared to Multiple Daily Injections

Condition:   Type 2 Diabetes Treated With Insulin
Intervention:   Drug: Afrezza Inhalant Product
Sponsors:   Diabetes and Glandular Disease Clinic;   Mannkind Corporation;   DexCom, Inc.
Recruiting

Type 2 Diabetes Prevention Toolkit for Health-Care Professionals

Condition:   Childhood Obesity
Intervention:   Behavioral: Evaluation of whiteboard videos
Sponsors:   The Hospital for Sick Children;   University of Ottawa
Not yet recruiting

A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus

Conditions:   Diabetes Mellitus, Type 2;   Hypoglycemia
Interventions:   Drug: Tirzepatide;   Drug: Placebo
Sponsor:   Eli Lilly and Company
Not yet recruiting

Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: empagliflozin
Sponsor:   Novo Nordisk A/S
Completed

Electronic Decision Support for Intervention in Poorly Controlled Type 2 Diabetes

Condition:   Diabetes Mellitus
Intervention:   Other: PATH electronic decision support tool
Sponsors:   St Elizabeth Healthcare;   PATH Decision Support Software, LLC
Completed

Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes.

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: Dulaglutide
Sponsor:   Novo Nordisk A/S
Completed

A Study of LY2409021 in Participants With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: LY2409021;   Drug: Sitagliptin;   Drug: Placebo;   Drug: Metformin;   Drug: Sulfonylurea
Sponsor:   Eli Lilly and Company
Terminated

Improving Medication Adherence Among Underserved Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Behavioral: REACH;   Behavioral: Helpline and A1c results;   Behavioral: REACH + FAMS
Sponsors:   Vanderbilt University Medical Center;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Completed

A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Semaglutide;   Drug: Placebo (semaglutide)
Sponsor:   Novo Nordisk A/S
Recruiting

A Research Study Comparing a New Medicine Oral Semaglutide to Sitagliptin in People With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Oral semaglutide;   Drug: Sitagliptin;   Drug: Placebo (oral semaglutide);   Drug: Placebo (sitagliptin)
Sponsor:   Novo Nordisk A/S
Recruiting

A Research Study Comparing a New Medicine Oral Semaglutide to Placebo in People With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Oral semaglutide;   Drug: Placebo
Sponsor:   Novo Nordisk A/S
Recruiting

Ferric Carboxymaltose in Type 2 Diabetes Mellitus (T2DM) Patients With Iron Deficiency

Conditions:   Type 2 Diabetes Mellitus;   Iron Deficiency
Interventions:   Drug: ferric carboxymaltose;   Drug: NaCl (0,9%)
Sponsors:   GWT-TUD GmbH;   Vifor Pharma
Active, not recruiting

Effects of 5 Weeks Treatment With Dapagliflozin in Type 2 Diabetes Patients on How the Hormone Insulin Acts on Sugar Uptake in Muscles.

Conditions:   Diabetes Mellitus, Type 2;   Skeletal Muscle Insulin Sensitivity
Intervention:   Drug: Dapagliflozin
Sponsor:   AstraZeneca
Active, not recruiting

Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: Semaglutide;   Drug: Liraglutide
Sponsor:   Novo Nordisk A/S
Completed

A Research Study in People With Type 2 Diabetes to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Insulin 287;   Drug: Insulin glargine U100
Sponsor:   Novo Nordisk A/S
Active, not recruiting

A Trial Investigating the Effect of Oral Semaglutide Compared With Placebo on Postprandial Glucose and Triglyceride Metabolism, Energy Intake, Appetite Sensations and Gastric Emptying in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Completed

Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Semaglutide;   Drug: Standard of care
Sponsor:   Novo Nordisk A/S
Recruiting

A Research Study to Compare Insulin 287 Once a Week to Insulin Glargine (100 Units/mL) Once a Day in People With Type 2 Diabetes.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Insulin 287;   Drug: Placebo (insulin 287);   Drug: Metformin;   Drug: Dipeptidyl peptidase-4 inhibitors;   Drug: Insulin glargine;   Drug: Placebo (insulin glargine)
Sponsor:   Novo Nordisk A/S
Active, not recruiting

A Dose Range Finding Study to Evaluate the Effect of Bexagliflozin Tablets in Subjects With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Bexagliflozin tablets;   Drug: Bexagliflozin tablets, placebo
Sponsor:   Theracos
Completed

A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Semaglutide;   Drug: Insulin aspart;   Drug: Insulin glargine U100
Sponsor:   Novo Nordisk A/S
Recruiting

DISCOVER Global Registry

Condition:   Type 2 Diabetes
Intervention:  
Sponsor:   AstraZeneca
Recruiting

A Multiple Ascending Dose Study to Evaluate Safety and Tolerability of BFKB8488A in Participants With Type 2 Diabetes Mellitus and Participants With Non-Alcoholic Fatty Liver Disease

Conditions:   Diabetes Mellitus, Type 2;   Non-Alcoholic Fatty Liver Disease
Interventions:   Drug: BFKB8488A;   Other: Placebo
Sponsor:   Genentech, Inc.
Recruiting

Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Completed

A Research Study to Compare Two Doses of Semaglutide Taken Once Weekly in People With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Semaglutide;   Drug: Placebo (semaglutide)
Sponsor:   Novo Nordisk A/S
Recruiting

Exergaming Versus Aerobic Exercises on Mild Cognitive Impairment

Conditions:   Type 2 Diabetes;   Cognitive Impairment
Interventions:   Other: Exergaming Training Group;   Other: Aerobic Exercise Group
Sponsor:   Riphah International University
Completed

Determining the Minimal Amount of Exercise to Improve Glycaemic Control

Condition:   Type 2 Diabetes
Intervention:   Other: Cycle ergometry exercise at 60% VO2max
Sponsor:   Lancaster University
Recruiting

Visualizing Beta Cells After Bariatric Surgery

Condition:   Type 2 Diabetes Mellitus
Intervention:   Radiation: 68Ga-exendin PET/CT
Sponsors:   Radboud University;   Rijnstate Hospital
Recruiting

A Phase IV Study in Drug-Naive Patients With T2DM in China

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Dapagliflozin;   Drug: Acarbose
Sponsor:   AstraZeneca
Recruiting

GLP1-imaging Before and After Bariatric Surgery

Conditions:   Diabetes Mellitus, Type 2;   Bariatric Surgery Candidate
Intervention:   Radiation: 68Ga-NODAGA-exendin-4 PET/CT
Sponsors:   Radboud University;   Rijnstate Hospital
Recruiting

Genetic Variants Replication Study Associated With Dependence on Sulfonylurea in Participants With Type 2 Diabetes

Condition:   Diabetes Mellitus
Intervention:   Drug: discontinuation of Sulfonylureas
Sponsor:   Seoul National University Hospital
Recruiting

A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in France, as Part of Local Clinical Practice (SURE FRANCE)

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: semaglutide
Sponsor:   Novo Nordisk A/S
Enrolling by invitation

A Research Study, Looking at How Ryzodeg® (Insulin Degludec/Insulin Aspart) Works in People With Type 2 Diabetes in Local Clinical Practice

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Insulin Degludec/Insulin Aspart
Sponsor:   Novo Nordisk A/S
Enrolling by invitation

A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in The Netherlands, as Part of Local Clinical Practice (SURE NETHERLANDS)

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: semaglutide
Sponsor:   Novo Nordisk A/S
Enrolling by invitation

A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Glimepiride;   Drug: Metformin;   Drug: Pioglitazone;   Drug: Acarbose;   Drug: Linagliptin;   Drug: Sitagliptin;   Drug: Liraglutide;   Drug: Insulin Glargine;   Drug: Exenatide once weekly (QW);   Drug: Exenatide twice daily (BID)
Sponsor:   Eli Lilly and Company
Terminated

A Study to Investigate the Efficacy and Safety of Canagliflozin in Children and Adolescents (>=10 to <18 Years) With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Canagliflozin 100 mg;   Drug: Canagliflozin 300 mg;   Drug: Placebo
Sponsor:   Janssen Research & Development, LLC
Recruiting

Efficacy and Safety of EGT0001442 in Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus
Interventions:   Drug: EGT0001442;   Drug: Placebo
Sponsor:   Theracos
Completed

Utilizing Glycaemic Index: An Investigation of the Glycaemia and Cognition in Type 2 Diabetes

Conditions:   Diabetes Mellitus, Type 2;   Cognitive Impairment
Interventions:   Dietary Supplement: Low Glycaemic Diet;   Dietary Supplement: High Glycaemic Diet
Sponsor:   Matthew Grout
Completed

A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Italy, as Part of Local Clinical Practice

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Semaglutide
Sponsor:   Novo Nordisk A/S
Not yet recruiting

A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Spain, as Part of Local Clinical Practice

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Semaglutide
Sponsor:   Novo Nordisk A/S
Enrolling by invitation

A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Switzerland, as Part of Local Clinical Practice (SURE SWITZERLAND)

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Semaglutide
Sponsor:   Novo Nordisk A/S
Active, not recruiting

A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Denmark and Sweden, as Part of Local Clinical Practice (SURE DENMARK/SWEDEN)

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Semaglutide
Sponsor:   Novo Nordisk A/S
Active, not recruiting

Characterization of Retinal Vascular Disease in Eyes With Mild to Moderate NPDR in Diabetes Type 2

Condition:   NPDR - Non Proliferative Diabetic Retinopathy
Intervention:   Diagnostic Test: Laboratory tests
Sponsors:   Association for Innovation and Biomedical Research on Light and Image;   Fundação para a Ciência e a Tecnologia
Recruiting

Specific Clinical Experience Investigation for Long-term Use of Bydureon.

Condition:   Type 2 Diabetes
Intervention:  
Sponsor:   AstraZeneca
Active, not recruiting

Metabolic Activation With Protein-rich Formula Diet

Condition:   Type 2 Diabetes Mellitus
Interventions:   Dietary Supplement: stringent diet regimen;   Dietary Supplement: moderate diet regimen
Sponsors:   West German Center of Diabetes and Health;   Almased Wellness GmbH
Recruiting

A Study Based on Data From German Registries That Looks at Characteristics of People Who Take the Medicine Empagliflozin for Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Empagliflozin
Sponsor:   Boehringer Ingelheim
Active, not recruiting

Post-authorization Safety Study in Type 2 Diabetic Patients in Saudi Arabia Treated With Empagliflozin to Assess the Incidence of Ketoacidosis, Severe Complications of Urinary Tract Infection, Volume Depletion, and Dehydration

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Empagliflozin;   Drug: Dipeptidyl-peptidase 4 (DPP-4) inhibitors
Sponsor:   Boehringer Ingelheim
Recruiting

A 12 Month Site Randomized Trial in Adults With Type 2 Diabetes Mellitus and History of Cardiovascular Disease

Conditions:   Diabetes Mellitus, Type 2;   Cardiovascular Diseases
Intervention:   Other: Intense Education Intervention
Sponsors:   Duke University;   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting

Specific Clinical Experience Investigation for Long-term Use of Exenatide (Byetta Subcutaneous Injection)

Condition:   Type 2 Diabetes
Intervention:  
Sponsor:   AstraZeneca
Completed

Surgical or Medical Treatment

Conditions:   Diabetes Mellitus, Type 2;   Pediatric Obesity;   Bariatric Surgery Candidate
Interventions:   Procedure: Bariatric Surgery;   Drug: Advanced Medical Therapy
Sponsors:   Children's Hospital Medical Center, Cincinnati;   Children's Hospital Colorado
Not yet recruiting

Effect of Empagliflozin on Body Composition and Ketones

Conditions:   Diabetes Mellitus;   Fat; Intolerance, Pancreas
Interventions:   Drug: Empagliflozin 10 MG;   Drug: Hypoglycemics Oral
Sponsor:   Seoul National University Bundang Hospital
Recruiting

Insulin Sensitivity in Patients With Atopic Dermatitis

Conditions:   Atopic Dermatitis/Eczema;   Type 2 Diabetes
Intervention:   Diagnostic Test: Hyperinsulinemic euglycemic clamp
Sponsor:   University Hospital, Gentofte, Copenhagen
Completed

Initial Combination of Gemigliptin and Metformin on Microbiota Change

Condition:   Diabetes
Interventions:   Drug: gemigliptin/metformin;   Drug: glimepiride/metformin
Sponsor:   Seoul National University Bundang Hospital
Recruiting

Acute Kidney Injury in Patients on Dapagliflozin and Other Antidiabetic Medications

Condition:   Acute Kidney Injury
Intervention:  
Sponsor:   AstraZeneca
Recruiting

Acute Liver Injury in Patients on Dapagliflozin

Condition:   Acute Liver Injury
Intervention:  
Sponsor:   AstraZeneca
Recruiting

Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Linagliptin;   Drug: Empagliflozin;   Drug: Placebo
Sponsor:   Boehringer Ingelheim
Recruiting

Beta Cell Restoration Through Fat Mitigation

Conditions:   Prediabetes;   Type 2 Diabetes;   Obesity
Interventions:   Drug: Metformin;   Device: gastric banding
Sponsors:   University of Southern California;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Completed

Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

Conditions:   Cardiovascular Disease;   Diabetes Mellitus, Type 2
Interventions:   Drug: Dulaglutide;   Drug: Placebo
Sponsor:   Eli Lilly and Company
Completed

Complications of UTI in Patients on Dapagliflozin

Condition:   Severe Complications of Urinary Tract Infections
Intervention:  
Sponsor:   AstraZeneca
Recruiting

Urinary Vitamin C Loss in Diabetic Subjects

Conditions:   Diabetes Type 1;   Diabetes Type 2;   Healthy Volunteers
Intervention:  
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting

Cancer in Patients on Dapagliflozin and Other Antidiabetic Treatment

Conditions:   Breast Cancer;   Bladder Cancer
Intervention:  
Sponsor:   AstraZeneca
Recruiting

A Study of Single or Repeated Doses of Glucagon in Participants With Diabetes

Conditions:   Diabetes Mellitus, Type 1;   Diabetes Mellitus, Type 2
Intervention:   Drug: Nasal Glucagon
Sponsors:   Eli Lilly and Company;   Locemia Solutions ULC
Completed

Renal Oxygenation, Oxygen Consumption and Hemodynamic Kinetics in Type 2 DIabetes: an Ertugliflozin Study.

Conditions:   Type 2 Diabetes Mellitus;   Diabetic Kidney Disease;   Diabetic Nephropathy;   Renal Hypoxia;   Renoprotection;   SGLT2 Inhibitor;   Ertugliflozin
Intervention:   Drug: Ertugliflozin 15 mg
Sponsor:   VU University Medical Center
Not yet recruiting

Non-REm Sleep inTervention to improvE Diabetes RESTED

Condition:   Type 2 Diabetes
Interventions:   Other: Sleep Audiological Intervention Device (SleepAID);   Other: sham control
Sponsors:   University of Lincoln;   University of Leeds
Recruiting

Comparison of Lobeglitazone With Pioglitazone as Initial Triple Therapy for Diabetes Management

Condition:   Type 2 Diabetes
Interventions:   Drug: Pioglitazone;   Drug: Lobeglitazone
Sponsor:   Seoul National University Bundang Hospital
Recruiting

Empaglifozin in Early Diabetic Kidney Disease

Conditions:   Diabetic Kidney Disease;   Diabetes Mellitus Type 2
Interventions:   Drug: Empagliflozin;   Other: Placebo
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Not yet recruiting

An Ascending Dose, Single/Multiple Dosing, Food Effect Clinical Trial to Evaluate Pharmacokinetics, Safety and Tolerability in Healthy Subjects After Oral Administration of Gemigliptin (Phase I)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Gemigliptin 25mg;   Drug: Gemigliptin 50mg;   Drug: Gemigliptin 100mg;   Drug: Gemiglptin 50mg multiple dose
Sponsor:   LG Chem
Active, not recruiting

Safety and Efficacy of Dapagliflozin in Asian T2DM Subjects With Inadequate Glycemic Control on Metformin/Saxagliptin

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Dapagliflozin 10 mg;   Drug: Dapagliflozin 5 mg;   Drug: Dapagliflozin 10 mg placebo to match;   Drug: Dapagliflozin 5 mg placebo to match;   Drug: Saxagliptin 5 mg;   Drug: Metformin
Sponsor:   AstraZeneca
Recruiting

Genetics of Obesity, Diabetes, and Heart Disease in African Diaspora Populations

Conditions:   Diabetes;   Cardiovascular Disease
Intervention:  
Sponsor:   National Human Genome Research Institute (NHGRI)
Enrolling by invitation

Mapping Genes for Type 2 (Non-Insulin Dependent) Diabetes Mellitus

Conditions:   Genetic Variation;   Diabetes
Intervention:  
Sponsor:   National Human Genome Research Institute (NHGRI)
Recruiting

Quantification of CD163 Inflammatory Biomarker in Chronic Periodontitis and Diabetic Subjects

Condition:   Periodontal Diseases
Intervention:  
Sponsor:   Meenakshi Ammal Dental College and Hospital
Recruiting

A Study of HTD1801 in Adults With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM)

Conditions:   Fatty Liver, Nonalcoholic;   NAFLD;   Nonalcoholic Fatty Liver Disease;   Nonalcoholic Steatohepatitis;   Digestive System Diseases
Interventions:   Drug: HTD1801;   Drug: Placebo
Sponsor:   HighTide Biopharma Pty Ltd
Recruiting

Effectiveness and Implementation of the Assessment of Burden of Chronic Conditions (ABCC)-Tool

Conditions:   Chronic Obstructive Pulmonary Disease;   Asthma;   Diabetes Mellitus, Type 2;   Heart Failure
Intervention:   Device: Assessment of Burden of Chronic Conditions (ABCC)-tool
Sponsors:   Maastricht University;   Netherlands Instititute for Health Services Research;   TNO;   University of Twente
Recruiting

Bisphenol A and Muscle Insulin Sensitivity

Conditions:   Insulin Sensitivity;   Glucose Metabolism Disorders;   Microtia
Interventions:   Behavioral: bisphenol A;   Behavioral: Placebo
Sponsors:   California Polytechnic State University-San Luis Obispo;   American Diabetes Association
Recruiting

Short-term Sugary Beverage Consumption on Glucose Control and Cardiovascular Disease Risk Factors

Condition:   Metabolic Syndrome
Interventions:   Dietary Supplement: Sugary beverage: Fruit juice;   Dietary Supplement: Sugary beverage: Soda;   Dietary Supplement: Control: Water
Sponsor:   Kansas State University
Completed

Piloting Diet and Exercise Interventions in Older Hispanics With Diabetes

Conditions:   Diabetes;   Senior Syndrome;   Frailty
Interventions:   Behavioral: Diet;   Behavioral: Exercise;   Behavioral: Diet and exercise
Sponsor:   Florida International University
Recruiting

Impact of Semaglutide on CD34+ EPC and Fat Derived MSC

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Semaglutide;   Drug: Placebos
Sponsor:   Sabyasachi Sen
Recruiting

Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT)

Conditions:   Type2 Diabetes;   Dyslipidemia
Interventions:   Drug: K-877;   Drug: Placebo
Sponsors:   Kowa Research Institute, Inc.;   Brigham and Women's Hospital
Recruiting

A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (C) Semaglutide Tablets

Conditions:   Healthy Volunteers;   Type 2 Diabetes
Intervention:   Drug: Oral semaglutide
Sponsor:   Novo Nordisk A/S
Recruiting

Effect of Weight Loss Surgery on Stem Cells.

Conditions:   Obesity, Morbid;   Stem Cells;   Cardiovascular Morbidity
Intervention:   Procedure: Bariatric (weight loss) surgery
Sponsors:   St. Michael's Hospital, Toronto;   Humber River Hospital;   University of Western Ontario, Canada
Completed

Preventing Diabetes in Latino Youth

Conditions:   Obesity;   Diabetes
Interventions:   Behavioral: Intensive Lifestyle Intervention;   Other: Usual Care Control
Sponsors:   Arizona State University;   Phoenix Children's Hospital;   St. Vincent de Paul Medical and Dental Clinic;   Valley of the Sun YMCA, Arizona;   University of Washington;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Active, not recruiting

The Effects of Evolocumab in Patients With Diabetes and Atherosclerotic Vascular Disease

Conditions:   Atherosclerotic Vascular Disease;   Type2 Diabetes;   Microvascular Dysfunction
Interventions:   Drug: Placebo;   Drug: Evolocumab
Sponsors:   Robert Rosenson;   Amgen;   University of Toronto;   University of Michigan
Recruiting

ELO Water In Diabetes Care For Enhancement Of Blood Sugar Control (EDEN Study) - A Double-Blinded Randomized Controlled Trial

Condition:   Diabetes Mellitus
Interventions:   Dietary Supplement: ELO Water;   Dietary Supplement: Placebo drinking water
Sponsors:   Changi General Hospital;   ELOWater Pte Ltd
Completed

Molecular and Clinical Profile of Diabetes Mellitus and Its Complications

Conditions:   Diabetes Mellitus, Type 2;   Diabetic Nephropathy;   Obesity
Intervention:  
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Suspended

Acute Effects of Canagliflozin, a Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor on Bone Metabolism in Healthy Volunteers

Condition:   Healthy Volunteers
Interventions:   Drug: Placebo;   Drug: Canagliflozin
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Completed

Combined Effects of Diabetes Self-Management Education and Nutritional Supplementation on Visual Function and Retinopathy

Conditions:   Diabetes Mellitus;   Diabetic Retinopathy
Intervention:   Dietary Supplement: EyePromise DVS, EyePromise DVS plus EyePromise EZTears
Sponsor:   ZeaVision, LLC
Recruiting

Preliminary Exploration on the Operational Standards of Insulin Pump Installation in Diabetes Clinic in China

Conditions:   Type 1 Diabetes Mellitus;   Type 2 Diabetes Mellitus;   Gestational Diabetes Mellitus;   Pancreatogenic Diabetes Mellitus;   Pregestational Diabetes Mellitus;   Diabetes Patients in Perioperative Period
Intervention:   Device: Insulin pump (Microtech, Equil®)
Sponsor:   Peking Union Medical College Hospital
Not yet recruiting

Mobile Health Application for Diabetes

Condition:   Diabetes Mellitus, Type 2
Intervention:   Behavioral: capABILITY
Sponsor:   University of South Alabama
Completed

Injection of Subcutaneous Glucose 10% in Small Shots is Effective in the Treatment of Diabetic Neuropathic Pain

Condition:   Painful Diabetic Neuropathy
Intervention:   Drug: GLUCOSE 10%
Sponsor:   Ministry of Health and Population, Egypt
Recruiting

Effect of Empagliflozin + Linagliptin + Metformin + Lifestyle in Patients With Prediabetes

Conditions:   Prediabetic State;   Insulin Resistance
Interventions:   Combination Product: Linagliptin + metformin and Empagliflozin + metformin;   Drug: Metformin
Sponsors:   Universidad de Guanajuato;   Hospital Regional de Alta Especialidad del Bajio
Recruiting

Effect of Self- and Family Management of Diabetic Foot Ulcers Programs on Health Outcomes

Conditions:   Diabete Mellitus;   Diabetic Foot
Interventions:   Behavioral: Self-and family management of diabetic foot ulcers programs;   Other: Usual care
Sponsor:   Universitas Muhammadiyah
Active, not recruiting

The SIMBA Project - The Effect of a Prebiotic Supplement on Glucose Metabolism and Gut Microbiota in Obese Adults

Conditions:   Glucose Metabolism;   Metabolic Syndrome;   Gut Microbiota
Interventions:   Dietary Supplement: Fermented canola-seaweed;   Other: Placebo
Sponsors:   University of Copenhagen;   FermBiotics ApS
Not yet recruiting

A Biological Atlas of Severe Obesity (Biological Tissue Collection)

Conditions:   Obesity;   Glucose Intolerance;   Diabetes
Intervention:  
Sponsor:   University Hospital, Lille
Recruiting

A French Study to Evaluate the Usefulness of Implantable Continuous Glucose Monitoring (CGM) Sensor to Improve Glycemic Control in Participants With Diabetes Mellitus.

Condition:   Diabetes Mellitus
Interventions:   Device: Eversense XL;   Device: Usual SMBG or FGM device used by participants
Sponsors:   Hoffmann-La Roche;   Roche Diabetes Care France SAS
Recruiting

Vitamin E Pharmacokinetics and Biomarkers in Normal and Obese Women

Conditions:   Diabetes;   Fatty Liver;   Obesity;   Healthy Volunteers
Interventions:   Drug: Alpha Tocopherol Vitamin E;   Other: Vitamin C
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting

A Study of LY900020 in Healthy Chinese Participants

Condition:   Healthy
Interventions:   Drug: LY900020;   Drug: Metformin XR;   Drug: Atorvastatin;   Drug: Valsartan
Sponsor:   Eli Lilly and Company
Not yet recruiting

Effects of Metformin During Nicotine Withdrawal

Conditions:   Smoking;   HIV-1-infection
Interventions:   Drug: Metformin;   Drug: Placebo
Sponsors:   University of Pennsylvania;   Pennsylvania Department of Health
Recruiting

Addressing Basic Needs to Improve Diabetes Outcomes in Medicaid Beneficiaries

Condition:   Diabetes Mellitus, Type 2
Intervention:   Behavioral: Basic needs navigation
Sponsors:   Washington University School of Medicine;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);   Louisiana Healthcare Connections
Not yet recruiting

A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus

Condition:   Diabetes Mellitus
Interventions:   Drug: Glucagon Nasal Powder;   Drug: Glucagon Hydrochloride Solution
Sponsor:   Eli Lilly and Company
Completed

Effect of Time-Restricted Feeding on 24-hour Glycemic Control, Blood Pressure, and Cardiovascular Disease Risk Factors

Condition:   PreDiabetes
Interventions:   Behavioral: Early Time-Restricted Feeding;   Behavioral: Mid-day Time-Restricted Feeding;   Behavioral: Control Schedule
Sponsor:   University of Alabama at Birmingham
Not yet recruiting

The Combined Portfolio Diet and Exercise Study

Conditions:   Cardiovascular Diseases;   Hypercholesterolemia;   Type 2 Diabetes;   Metabolic Syndrome
Interventions:   Behavioral: Portfolio diet and structured exercise;   Behavioral: DASH-like diet and structured exercise;   Behavioral: Portfolio diet and routine exercise;   Behavioral: DASH-like diet and routine exercise
Sponsors:   St. Michael's Hospital, Toronto;   Canadian Institutes of Health Research (CIHR);   University of Toronto;   Laval University;   University of Manitoba;   University of British Columbia
Recruiting

The Effect of Liraglutide on Pancreatic Hormones and Its Size

Condition:   Obesity
Intervention:   Drug: Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml
Sponsors:   Nicolai Jacob Wewer Albrechtsen;   Hvidovre University Hospital;   Rigshospitalet, Denmark
Active, not recruiting

CTSI Pilot: Improving Adherence to Diabetic Diet

Conditions:   Diabetes Mellitus, Type 2;   Diet, Healthy;   Pre-diabetes
Interventions:   Behavioral: Online - use of online grocery shopping platform;   Behavioral: Default - use of online grocery shopping platform with default shopping carts
Sponsor:   State University of New York at Buffalo
Recruiting

Visualizing Beta Cells in Patients With a History of Gestational Diabetes

Condition:   Gestational Diabetes
Intervention:   Radiation: 68Ga-NODAGA-exendin-4 PET/CT
Sponsor:   Radboud University
Recruiting

Pathophysiology of Uric Acid Nephrolithiasis

Condition:   Uric Acid Kidney Stone Disease
Interventions:   Drug: Pioglitazone;   Drug: Placebo
Sponsors:   University of Texas Southwestern Medical Center;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);   Takeda Pharmaceuticals North America, Inc.
Recruiting

Lipid Profile and Diabetes Mellitus in People With HIV

Conditions:   HIV Infections;   Dyslipidemias;   Diabetes Mellitus;   Cardiovascular Risk Factor
Intervention:  
Sponsors:   Igor Grabovac;   Merck Gesellschaft mbH, Austria
Not yet recruiting

Resilient, Empowered, Active Living: REAL Diabetes Study

Conditions:   Diabetes Mellitus, Type 1;   Diabetes Mellitus, Type 2
Interventions:   Behavioral: Resilient, Empowered, Active Living with Diabetes;   Behavioral: Information Control
Sponsors:   University of Southern California;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Completed

Effects of Evolocumab on Platelet Reactivity in Patients With Diabetes Mellitus After Elective Percutaneous Coronary Intervention

Conditions:   Diabetes Mellitus, Type 2;   Dyslipidemia Associated With Type II Diabetes Mellitus;   Percutaneous Coronary Intervention
Interventions:   Drug: Evolocumab;   Drug: Placebo
Sponsor:   Inova Health Care Services
Terminated

Group Lifestyle Balance™ for Individuals With Stroke (GLB-CVA)

Condition:   Stroke
Interventions:   Behavioral: Group Lifestyle Balance;   Other: Usual Care
Sponsors:   Baylor Research Institute;   National Institute on Disability, Independent Living, and Rehabilitation Research
Recruiting

Effects of Wolffia Globosa (Mankai) in Patients Undergoing Bariatric Surgery.

Conditions:   Bariatric Surgery Candidate;   Diet Modification
Intervention:   Other: Dietary modification with introduction of Mankai
Sponsor:   Cleveland Clinic Florida
Recruiting

Intensive Lifestyle Intervention for Remission of Metabolic Syndrome

Condition:   Metabolic Syndrome
Interventions:   Behavioral: Intensive Lifestyle Intervention;   Behavioral: Conventional Treatment
Sponsor:   Second Affiliated Hospital, School of Medicine, Zhejiang University
Not yet recruiting

The Role of Proper Insulin Injection Technique in the Treatment of Diabetes. Mellitus

Conditions:   Diabetes Mellitus, Type 2;   Diabetes Mellitus, Type 1;   Lipohypertrophy
Intervention:   Behavioral: Optimal insulin injection
Sponsor:   Becton, Dickinson and Company
Recruiting

The Effect of Intraneural Facilitation Therapy on Diabetic Patients With Peripheral Neuropathy

Condition:   Diabetic Neuropathy
Interventions:   Other: Intraneural Facilitation;   Other: Sham
Sponsor:   Loma Linda University
Recruiting

Impact of Physiological, Lifestyle and Genetic Factors on Body Composition

Condition:   Body Composition, Beneficial
Intervention:  
Sponsor:   University of Reading
Completed

Teen-Longitudinal Assessment of Bariatric Surgery (Teen-LABS) Adolescent Bariatrics: Assessing Health Benefits and Risk

Condition:   Obesity
Intervention:  
Sponsors:   University of Colorado, Denver;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);   Children's Hospital Medical Center, Cincinnati;   University of Pittsburgh Medical Center;   University of Alabama at Birmingham;   Nationwide Children's Hospital;   Texas Children's Hospital;   University of Washington;   Sanford Health
Enrolling by invitation

Prevention of Chemotherapy-Related Polyneuropathy Via Sensorimotor Exercise Training

Conditions:   Exercise;   Chemotherapy-induced Polyneuropathy
Intervention:   Behavioral: Exercise
Sponsors:   German Cancer Research Center;   University Hospital Heidelberg;   National Center for Tumor Diseases, Heidelberg
Active, not recruiting

The Effects of BAY1193397 on Skin Capillary Blood Flow and Transcutaneous Oxygen Pressure

Condition:   Diabetic Foot
Interventions:   Drug: BAY1193397;   Drug: Placebo
Sponsor:   Bayer
Active, not recruiting

Improving Chronic Disease Management With Pieces

Conditions:   Chronic Kidney Disease;   Diabetes;   Hypertension;   High BP;   Type 2 Diabetes
Intervention:   Other: Collaborative Model of Primary care and Subspecialty care
Sponsors:   University of Texas Southwestern Medical Center;   Parkland Center for Clinical Innovation;   Parkland Health & Hospital System;   Texas Health Resources;   Connecticut Center for Primary Care;   Dallas VA Research Corporation;   G-Health Enterprises;   National Institutes of Health (NIH);   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);   National Heart, Lung, and Blood Institute (NHLBI)
Completed

Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy

Condition:   Diabetic Cardiomyopathies
Interventions:   Drug: AT-001;   Drug: Placebo
Sponsor:   Applied Therapeutics, Inc.
Recruiting

The Effect of Dopamine on Diabetic Retinopathy

Condition:   Diabetes
Interventions:   Drug: Low Dose Sinemet CR;   Drug: High Dose Sinemet CR;   Device: RETeval Electroretinogram (ERG) Testing;   Other: Contrast Sensitivity Testing;   Other: Visual Acuity Testing
Sponsor:   Emory University
Completed

e-NOBORI Observational Registry of Nobori DES

Condition:   Coronary Artery Disease
Intervention:  
Sponsor:   Terumo Europe N.V.
Completed

Study to Evaluate CORT125134 in Participants With Cushing's Syndrome

Condition:   Cushing's Syndrome
Intervention:   Drug: CORT125134
Sponsor:   Corcept Therapeutics
Completed

Monogenic Diabetes Misdiagnosed as Type 1

Conditions:   Diabetes Mellitus, Type 1;   Monogenic Diabetes;   Neonatal Diabetes;   Maturity-onset Diabetes in the Young (MODY);   Wolfram Syndrome;   Wolcott-Rallison Syndrome;   Mitochondrial Diabetes
Intervention:  
Sponsor:   Constantin Polychronakos
Recruiting

Research Study to Investigate How Well Semaglutide Works Compared to Liraglutide in People Living With Overweight or Obesity

Conditions:   Overweight;   Obesity
Interventions:   Drug: Semaglutide;   Drug: Placebo (semaglutide);   Drug: Liraglutide;   Drug: Placebo (liraglutide)
Sponsor:   Novo Nordisk A/S
Recruiting